OnKure Therapeutics (NASDAQ:OKUR) Trading 4% Higher – Here’s Why

OnKure Therapeutics (NASDAQ:OKUR) shares rose 4% during trading on Tuesday . The company traded as high as $9.38 and last traded at $8.60. Approximately 87,917 shares traded hands during trading, an increase of 110% from the average daily volume of 41,913 shares. The stock had previously closed at $8.27.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Leerink Partnrs upgraded OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Leerink Partners assumed coverage on shares of OnKure Therapeutics in a research report on Thursday, December 5th. They issued an “outperform” rating and a $33.00 price objective on the stock. Oppenheimer assumed coverage on shares of OnKure Therapeutics in a research report on Thursday, October 10th. They issued an “outperform” rating and a $35.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of OnKure Therapeutics in a report on Friday, November 8th. Finally, Lifesci Capital upgraded OnKure Therapeutics to a “strong-buy” rating in a research report on Thursday, October 10th. Three research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, OnKure Therapeutics has a consensus rating of “Buy” and an average target price of $36.00.

OnKure Therapeutics Stock Performance

The company has a market cap of $28.48 million, a PE ratio of -0.70 and a beta of 0.14. The stock’s 50-day moving average price is $13.78.

OnKure Therapeutics (NASDAQ:OKUR) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.13). On average, sell-side analysts predict that OnKure Therapeutics will post -4.05 earnings per share for the current fiscal year.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.